{A figure is presented}New and Emerging Treatment of Chronic Hepatitis B

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 3, 2007, Pages 285-294

  Keeffe, Emmet B ^a   Marcellin, Patrick ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE; TENOFOVIR; VALTORCITABINE; VIRUS DNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BINDING; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG TOLERANCE; FATIGUE; FEVER; HEPATITIS B; HUMAN; LIVER FAILURE; MONOTHERAPY; MYALGIA; NONHUMAN; RECOMMENDED DRUG DOSE; SEROCONVERSION; UNITED STATES; UNSPECIFIED SIDE EFFECT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FORECASTING; HOSPITALIZATION; MALE; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORECASTING; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; MALE; POLYETHYLENE GLYCOLS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33947110871     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.09.036     Document Type: Article

References (62)

1. Ganem D., and Prince A.M. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
2. Lai C.L., Ratziu V., Yuen M.F., et al. Viral hepatitis B. Lancet 362 (2003) 2089-2094
3. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
4. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of HBeAg-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
5. Lok A.S.F., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
6. Hadziyannis S., Tassopoulos N., Chang T.T., et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. (abstract). Hepatology 42 (2005) 754A
7. Brunetto M.R., Oliveri F., Coco B., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36 (2002) 263-270
8. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther In press.
9. Niederau C., Heintges T., Lange S., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
10. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
11. Lin S.M., Chien R.N., Sheen I.S., et al. Interferon therapy improves prognosis in patients with HBeAg positive chronic hepatitis B. (abstract). J Hepatol 42 Suppl 2 (2005) 149
12. Lin S.M., Tai D.I., Chien R.N., et al. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 11 (2004) 349-357
13. van Zonneveld M., Honkoop P., Hansen B.E., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 (2004) 804-810
14. Fattovich G., Giustina G., Sanchez-Tapias J., et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 93 (1998) 896-900
15. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
16. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
17. Yuan H.J., Yuen M.F., Ka-Ho W.D., et al. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat 12 (2005) 373-379
18. Tang B., Kruger W.D., Chen G., et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 72 (2004) 35-40
19. Yu M.W., Yeh S.H., Chen P.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97 (2005) 265-272
20. Innaimo S.F., Seifer M., Bisacchi G.S., et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 41 (1997) 1444-1448
21. Seifer M., Hamatake R.K., Colonno R.J., et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 42 (1998) 3200-3208
22. Levine S., Hernandez D., Yamanaka G., et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 46 (2002) 2525-2532
23. Colonno R.J., Genovesi E.V., Medina I., et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 184 (2001) 1236-1245
24. Foster W.K., Miller D.S., Scougall C.A., et al. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection. J Virol 79 (2005) 5819-5832
25. Marion P.L., Salazar F.H., Winters M.A., et al. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 46 (2002) 82-88
26. de Man R.A., Wolters L.M., Nevens F., et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34 (2001) 578-582
27. Lai C.L., Rosmawati M., Lao J., et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123 (2002) 1831-1838
28. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
29. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
30. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
31. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
32. Chang T.T., Chao Y.C., Sollano J., et al. Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (2006) (abstract). Presented at the Shanghai-Hong Kong International Liver Congress, March 25-28, Shanghai, China.
33. Shouval D., Akarca U., Hatzis G., et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg- chronic hepatitis B patients (study ETV-027). (abstract). J Hepatol 130 Suppl 2 (2006) S21-S22
34. Yurdaydin C., Sollano J., Hadziyannis S., et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg+ chronic hepatitis B patients (ETV-026). (abstract). J Hepatol 130 Suppl 2 (2006) S36
35. Colonno R., Rose R., Levine S., et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. (abstract). Hepatology 42 Suppl 1 (2005) A573-A574
36. Perry C.M., and Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 61 (2001) 2263-2288
37. Lindsay K.L., Trepo C., Heintges T., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34 (2001) 395-403
38. Reddy K.R., Wright T.L., Pockros P.J., et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33 (2001) 433-438
39. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
40. Chan H.L., Leung N.W., Hui A.Y., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142 (2005) 240-250
41. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
42. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
43. Chan H.L., Hui A.Y., Wong V.W., et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 41 (2005) 1357-1364
44. Lau G.K., Piratvisuth T., Thongsawat S., et al. Durability of response to peginterferon alfa-2a (40 KD) (PEGASYS) in Asian patients with HBeAg-positive chronic hepatitis B: 12 month follow-up data from a large, randomized study (2006) (abstract #49). Program and Abstracts of the 2006 Shanghai-Hong Kong International Liver Congress; March 25-28, Shanghai, China.
45. Marcellin P., Bonino F., Lau G.K., et al. Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2a (40KD) (Pegasys) monotherapy for HBeAg-negative chronic hepatitis B. (abstract). Hepatology 42 Suppl 1 (2005) A580
46. Gish R.G., Trinh H., Leung N., et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 43 (2005) 60-66
47. Lim S.G., Ng T.M., Kung N., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 166 (2006) 49-56
48. Lim S.G., Krastev Z., Ng T.M., et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 50 (2006) 1642-1648
49. Korba B.E., Cote P.J., Menne S., et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 9 (2004) 937-952
50. Marcellin P., Mommeja-Marin H., Sacks S.L., et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40 (2004) 140-148
51. Lee H.S., Chung Y.H., Lee K., et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 43 (2006) 982-988
52. Yuen M.F., and Lai C.L. Telbivudine: an upcoming agent for chronic hepatitis B. Expert Rev Anti Infect Ther 3 (2005) 489-494
53. Hodge R.A. Telbivudine/torcitabine Idenix/Novartis. Curr Opin Investig Drugs 5 (2004) 232-241
54. Lai C.L., Lim S.G., Brown N.A., et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40 (2004) 719-726
55. Lai C.L., Leung N., Teo E.K., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
56. Lai C.-L., Gane E., Liaw Y.-F., et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first-year results from the International Phase III Globe Trial. (abstract). Hepatology 42 Suppl 1 (2005) A748
57. Lai C.L., Brown N.A., Myers M., et al. Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: results of a phase I/II clinical trial. (abstract). Hepatology 40 Suppl 1 (2004) A173
58. Lim S.G., Lai C.-L., Gane E., et al. The antiviral efficacy of telbivudine is consistent across hepatitis B patient subgroups: results from the GOLBE study (2006) (abstract). Program and Abstracts From the Shanghai-Hong Kong International Liver Congress, March 25-28, Shanghai, China.
59. Lim S.G., Lai C.L., and Myers M. Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B. (abstract). J Hepatol 42 Suppl 2 (2005) 16
60. Benhamou Y., Fleury H., Trimoulet P., et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 (2006) 548-555
61. van Bommel F., Wunsche T., Mauss S., et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40 (2004) 1421-1425
62. Dore G.J., Cooper D.A., Pozniak A.L., et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 189 (2004) 1185-1192